PTO/SB/81 (04-05)
Approved for use through 11/30/2005. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM

Application Number	mation unless it displays a valid OMB control number.			
Filing Date	October 14, 2005			
First Named Inventor	Giampiero de Luca			
Title	Interferon Beta in Severe Acute			
Art Unit				
Examiner Name				
Attorney Docket Number	SER-104			

I hereby revoke a	Il previous powers o	of attorney given in	the above-ide	ntified applica	ation.	
I hereby appoint:						
Practitioners as	associated with the Customer Number:			557		
Practitioner(s) named below:						
	Name			Registration Number		
						
					,	
as my/our attorney(s) Trademark Office cor	or agent(s) to prosecute nected therewith.	the application identifie	d above, and to t	ransact all busine	ess in the United State	s Patent and
Please recognize or o	hange the corresponder	ice address for the abov	e-identified appli	cation to:		
The address associated with the above-mentioned Customer Number:						
OR						
The addres	s associated with Custon	ner Number				
OR	Todata Will Coola					
Firm or Individua	Name					
Address						
	•					
City			State		Zip	
Country Telephone			Email			
I am the:						
Applicant/Inv	entor.					
Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)						
SIGNATURE of Applicant or Assignee of Record						
Signature					Date	
Name	Giampiero de Luca			Ĺ	elephone	
Title and Company						
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.						
*Total of	forms are subn	nitted.				

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	Interferon Beta in Severe Acute Respiratory Syndrome (SARS)				
As the belo	w named inventor(s), I/we declare that:				
This declar	ation is directed to:				
	The attached application, or				
	Application No. <u>PCT/EP2004/050456</u> , filed on <u>APRIL 6, 2004</u> ,				
	as amended on(if applicable);				
I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;					
I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;					
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.					
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.					
FULL NAM	E OF INVENTOR(S)				
Inventor one: GIAMPIERO DE LUCA					
Signature:	Citizen of: ITALY				
Inventor two):				
Signature:	Citizen of:				
Inventor thr	ee:				
Signature:	Citizen of:				
Inventor for	ır.				
Signature:	Citizen of:				
Addit	ional inventors or a legal representative are being named onadditional form(s) attached hereto.				

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.